Biological |
Cases associated with biological, n |
Total of reports of ADR, n |
ROR |
95%
CI |
Benralizumab |
62 |
4026 |
0.64 |
0.50-0.82 |
Breast Cancer
Lung Cancer
Malignant Melanoma
Pancreatic Carcinoma
|
4
3
3
3
|
|
0.69
0.94
1.92
1.60
|
0.26-1.84
0.30-2.92
0.62-5.97
0.52-4.96
|
Mepolizumab |
233 |
9920 |
0.98 |
0.86-1.12 |
Breast Cancer
Lung Cancer
Prostate Cancer
Colon Cancer
|
19
18
15
7
|
|
1.33
2.29
2.26
2.04
|
0.85-2.09
1.44-3.64
1.36-3.75
0.97-4.28
|
Reslizumab |
8 |
382 |
0.87 |
0.43-1.76 |
Dupilumab |
363 |
37602 |
0.40 |
0.36-0.44 |
Breast Cancer
Cutaneous T-cell lymphoma
Lymphoma
Lung Cancer
|
22
16
15
13
|
|
0.41
11.11
1.07
0.44
|
0.27-0.62
6.77-18.23
0.64-1.77
0.25-0.75
|
Omalizumab1 |
1380 |
36164 |
1.65 |
1.56-2.74 |